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In this issue of the Journal, Qin et al. (1) present data that
indicate that suppressors of cytokine signaling 1 (SOCS1)
are important mediators in controlling vascular changes
because of alloimmune reactions after transplantation.
After heart transplantation (HTx), the heart endures
various forms of attack from the immune system. Directly
after transplantation, preformed antibodies can damage the
arteries in the allografted heart by complement-mediated
lysis and antibody-dependent cell-mediated cytotoxicity
(hyperacute rejection). This rejection, which destroys the
transplanted heart within a period of hours to days, can be
overcome by pre-screening the patient’s serum for antibodies
against donor antigens (2).
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In a next phase, the transplanted organ is invaded and
attacked by cytotoxic T cells directed mainly to mismatched
human leukocyte antigens. After HTx, this acute rejection is
well controlled by immunosuppressive medication.
Cyclosporine-A, steroids, and azathioprine were drugs of
choice in early days. Today these drugs are, in part, replaced
by tacrolimus, mycophenolate mofetil, and rapamycin.
These drugs act against T- and B-cell activation by inhib-
iting either their proliferation, nonspeciﬁcally, or by inter-
fering with the cytokine production or activation pathways.
As T cells are considered the most potent effector cells in
acute rejection, direct killing of these cells by various types of
anti–T-cell antibodies also is used but is limited to therapy
for severe rejection episodes (3). The role of antibodies in the
process of allograft rejection has been underestimated for
a long time, but recently renewed interest in antibody-
mediated rejection mechanisms has shown that antibodies
formed after transplantation can be the cause of unknown*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the author and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Division of Molecular and Immunopathology, Department of Pathology,
University Medical Center Utrecht, Utrecht, the Netherlands. Dr. de Weger has re-
ported that he has no relationships relevant to the contents of this paper to disclose.heart failure after transplantation or can play a role in
chronic rejection (4).
The heart having overcome acute rejection, a new
“rejection” process emerges: chronic rejection in HTx, called
cardiac allograft vasculopathy (CAV) or graft arteriosclerosis
(GA). With other transplanted organs, chronic rejection also
occurs but is not necessarily limited to the vasculature (e.g.,
Brochiolitis obliterans infection after lung transplantation),
but the processes are most likely mechanistically related. In
GA, the lumen of the coronary arteries is compromised by
the growth of the intima. Normal coronary arteries are
composed, from outside inward, of the adventitia (connec-
tive tissue with a rich vasculature), the lamina elastica
externa, the media (circular smooth muscle cells [SMCs]),
the lamina elastica interna (a recently described layer of
longitudinally-oriented SMCs, called SMC neo-intima [5]
or benign intimal thickening [6]), and ﬁnally, the endo-
thelial layer and lumen. After HTx, between the benign
intimal thickening and the endothelial layers is the forma-
tion of a new layer of loose connective tissue ﬁlled with
mononuclear cells that slowly compromise the lumen (neo-
intima luminal layer [5]). In time, the layer of loose
connective tissue becomes more densely populated with
(angio) ﬁbroblasts, resulting ﬁnally in a collagenous
connective tissue. The mechanism behind this process is
generally believed to be mediated by T helper 1 cells that
produce proﬁbrogenic cytokines that induce a proliferative
chronic ﬁbrosis (7). Although T cells are considered, again,
the main effector or inducer cells for this proliferation, the
drugs that are effective in suppressing T-cell activity in acute
rejection seem to have little effect in this process. However,
it should be noted that HTx patients who develop CAV are
undergoing constant immunosuppressive therapy and that
analysis of the cytokines produced indicate that, indeed,
most cytokines are suppressed except for transforming
growth factor (TGF)-b 2014 and interferon (IFN)-g, which
are less sensitive to the immunosuppressive drugs used (5,7).
Thus, in humans, another way to suppress CAV may not be
to target the immune response and T cells but to target the
ﬁbrosis itself by using drugs that interfere with ﬁbroblast
proliferation and collagen production. Two drugs in
particular have been used for that purpose: rapamycin/siro-
limus and everolimus. So far, these drugs have been used
with variable success in human HTx. However, a recent
study did indicate that targeting ﬁbrosis may be a valuable
option in chronic rejection (8).
Research of chronic rejection is severely hampered by the
lack of good animal models, as rat-rat or mouse-mouse
vascular transplantation results in a form of occlusive vascul-
opathy caused mainly by the inﬂux and growth of SMCs and
not by a ﬁbrotic response. In 2000, Tellides and Pober (9)
introduced the humanized mouse model that best mimicked
the human situation. A human artery was transplanted in an
SCID-Beige immunocompromised mouse. After a week,
human lymphocytes allogeneic to the graft were injected.
Within 6 to 10 weeks, a vasculopathy was induced that
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This group analyzed the mechanism of graft arteriosclerosis in
this model with great success, showing again the important
roles of both TGF-b and IFN-g. Importantly, the authors
showed that both TGF-b and IFN-g were involved in the
induction of ﬁbrosis, suggesting that either the cytokines
directly or the induction of the proliferative response in the
ﬁbroblasts are good targets for therapy (10,11).
In the present paper, Qin et al. (1) show a completely
new approach in the mouse-to-mouse model. Instead of
targeting cytokines or T cells directly or interfering with
ﬁbrosis pathways, the authors studied the role of the regu-
lation of cytokine signals in GA. They studied the role of
endothelial cell (EC) SOCS1 expression in the develop-
ment of GA by using a murine vascular transplant model
(Minor MHC H-Y-disparity between donor and recipient)
and by analyzing human arteries with and without GA. In
human GA arteries, a dramatic decrease in SOCS1 was
observed, suggesting an important role for SOCS1 in pre-
venting GA development. This was conﬁrmed in various
experimental models by using SOCS1 transgenic and
knock-out mice. The inﬂux of inﬂammatory cells and
intima proliferation were inversely related to SOCS1
expression in EC. This suggested that SOCS1 blocks the
cytokine signaling (not the production of IFN-g and
interleukin-6 that induced adhesion molecule expression.
As a consequence, the inﬂux of inﬂammatory cells that
induce the intima proliferation was reduced. Therefore,
reduction in SOCS1 leads to an increased inﬂux of cells and
intima proliferation. The authors show, interestingly, that
SOCS1 blocks expression of the adhesion molecule
PECAM-1 by direct binding. The adhesion molecules
ICAM-1 and VCAM-1 are blocked by SOCS1 by the more
common inhibition of JAK or STAT signaling in ECs.
A disadvantage of the present study was that mouse
arteries were transplanted into other mice. As described
earlier, intima proliferation in this mouse-mouse model is
different from that in human GA. One of the differences is
that the intima proliferation in this mouse-mouse model
is fast (within 2 to 3 weeks), whereas in the human situation,
the process may take months or years. It would be inter-
esting to analyze the role of SOCS1 in that study’s
humanized mouse model, as the authors showed that
SOCS1 was present in normal human EC and reduced in
GA. On the other hand, if the inﬂux of inﬂammatory cells
can be regulated by regulating SOCS1 expression in EC,
this could be effective not only in GA but also in acute
rejection and maybe even in antibody-mediated rejection.
It is well known that the level of GA is correlated with
the severity of acute rejection and vascular changes and
that expression of adhesion molecules is involved in
acute rejection after HTx as well. Therefore, it could be an
attractive and effective way of reducing the acute phase
by regulating SOCS1 (or other SOCS) (12) and, as a
consequence, also reduce the chronic phase of rejection by
using the same drug treatment. So far, no drugs for SOCS1regulation are available, but miR155 (13–16) and
miR122 (17) are known to suppress SOCS1 in vivo, so
SOCS1 may be up-regulated by the use of miR155/122
antagomirs. Because it was shown that the reduced SOCS1
expression in human vascular grafts was not paralleled by
a reduction of mRNA, this post-transcriptional regulation
seems attractive and feasible.
Thus, a speculative new view of the regulation of transplant
rejection, both in acute and chronic rejection, by regulating
the regulators of cytokine signaling (SOCS) may lie ahead.
This regulation also may have additional beneﬁcial effects on,
for example, apoptotic processes in the graft (18) and on
stromal cells or macrophages in the graft (16,19).
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